President Trump's announcement of tariffs on imported generic medicines has sparked debate about the viability of U.S. production for low-cost drug manufacturers. The tariffs will be phased in over three years, starting with a two-year period without duties, followed by a 100% tariff for one year, and then escalating to 200%.
This proposal targets a global generic drug market valued at nearly $500 billion. Industry leaders, including John Murphy III, CEO of the Association for Accessible Medicines, emphasize that while they support U.S. manufacturing, structural challenges beyond tariffs hinder domestic production.
Generic drugs account for about 90% of U.S. prescriptions but represent a small portion of overall drug spending due to their low prices. Analysts warn that a 100-200% tariff could force many manufacturers to either absorb costs, pass them on to consumers, or exit the market altogether, particularly affecting those with thin profit margins.
Companies like Amphastar Pharmaceuticals and Hikma, which have substantial U.S. production, may fare better than others like Teva and Viatris, which rely more on overseas manufacturing. The ultimate impact on medicine prices remains uncertain, hinging on how the policy is implemented and the response from manufacturers.
Investors currently view the two-year implementation period as a chance for companies to adapt, but the specifics of the policy will be crucial in determining its long-term effects on the industry